- Home
- XFOR vs FBRX Comparison
XFOR vs FBRX Comparison
Compare XFOR & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | FBRX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 143 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 487.2M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | XFOR | FBRX |
|---|---|---|
| Price | $4.45 | $24.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.00 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 340.8K | 209.0K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.35 | $7.00 |
| 52 Week High | $4.83 | $35.80 |
Technical Indicators
Market Signals| Indicator | XFOR | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 37.61 |
| Support Level | $3.41 | $22.33 |
| Resistance Level | $4.57 | $34.44 |
| Average True Range (ATR) | 0.25 | 2.17 |
| MACD | 0.01 | -0.55 |
| Stochastic Oscillator | 68.84 | 4.45 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.